Targeting drug-resistant cancers: in silico repurposing of the cholesterol-lowering drug Ezetimibe for selective inhibition of aldo-keto reductase 1B10 (AKR1B10)
{{output}}
One of the major challenges in cancer treatment is drug resistance, often driven by overexpression of detoxifying enzymes such as aldo-keto reductase family 1 member B10 (AKR1B10). Highly expressed in several cancers, AKR1B10 contributes to chemotherapeutic fa... ...
